Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Financing Activities (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Cash from Financing Activities data on record, last reported at $3.1 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 61.76% year-over-year to $3.1 million; the TTM value through Sep 2025 reached $5.6 million, down 95.93%, while the annual FY2024 figure was $131.1 million, 147.31% up from the prior year.
  • Cash from Financing Activities reached $3.1 million in Q3 2025 per STOK's latest filing, up from $554000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $120.6 million in Q2 2024 and bottomed at $43000.0 in Q4 2022.
  • Average Cash from Financing Activities over 4 years is $15.7 million, with a median of $1.7 million recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 251254.17% in 2024, then plummeted 99.54% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at $43000.0 in 2022, then soared by 16976.74% to $7.3 million in 2023, then crashed by 92.26% to $568000.0 in 2024, then soared by 449.3% to $3.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $3.1 million in Q3 2025, $554000.0 in Q2 2025, and $1.4 million in Q1 2025.